Understand the source comparison
Comparison of DSIP to Other Sleep-Modulatory Peptides and Compounds
DSIP Modulates hypothalamic sleep-wake switch; reduces evening cortisol 2–2.5 mg SubQ, 3x weekly Increases delta wave density by 25–34%; minimal effect on REM Low. Occasional morning grogginess at >4 mg Best for stress-induced insomnia; works through cortisol
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- DSIP
- Modulates hypothalamic sleep-wake switch; reduces evening cortisol
- 2–2.5 mg SubQ, 3x weekly
- Increases delta wave density by 25–34%; minimal effect on REM
- Low. Occasional morning grogginess at >4 mg
- Best for stress-induced insomnia; works through cortisol normalisation rather than direct sedation
- Melatonin
- Binds MT1/MT2 receptors to signal darkness and facilitate circadian phase shift
- 0.5–5 mg oral, nightly
- Advances sleep onset but doesn't deepen sleep architecture
- Very low. Rare next-day drowsiness
- First-line for circadian misalignment (jet lag, shift work); minimal effect on sleep depth
- GHRP-2 / GHRP-6
- Growth hormone secretagogues that increase stage 3–4 sleep as secondary effect
- 100–300 mcg SubQ, nightly
- Increases slow-wave sleep by 15–20%
- Moderate. Hunger, water retention
- Primarily used for GH release; sleep benefit is secondary and inconsistent
- Selank
- Anxiolytic peptide; modulates GABA and serotonin pathways
- 250–500 mcg intranasal, daily
- Reduces sleep latency by reducing anxiety-driven hyperarousal
- Low. No sedation or dependency risk
- Better for anxiety-related insomnia than primary sleep disorders; doesn't directly alter sleep stages
- Epithalon
- Telomerase activator with reported circadian-regulating effects
- 5–10 mg SubQ, cycled 10–20 days
- Anecdotal reports of improved sleep quality; no polysomnography data
- Very low. Minimal documented effects
- Insufficient clinical evidence for insomnia; used primarily for anti-aging research
- DSIP's unique position in this comparison is its cortisol-modulating mechanism. Unlike melatonin, which signals the brain that it's night-time, or GABAergic compounds, which suppress arousal centres, DSIP reduces the hormonal interference (elevated cortisol) that prevents the brain's natural sleep mechanisms from activating. This makes it most effective in stress-driven insomnia, where the underlying issue is hyperarousal rather than circadian misalignment or insufficient sleep drive.
- Melatonin and DSIP are often combined in protocols targeting both circadian phase and stress-hormone normalisation. A small 2025 pilot study found that 2 mg DSIP plus 1 mg melatonin (both administered 90 minutes before bed) produced better sleep onset and maintenance outcomes than either compound alone. The combination addresses two separate pathways: melatonin shifts circadian phase earlier, and DSIP reduces cortisol-driven arousal that would otherwise delay sleep onset even with proper melatonin timing.